Anti-malarial landscape in Myanmar: results from a nationally representative survey among community health workers and the private sector outlets in 2015/2016

Table 4 Private sector availability of anti-malarial drugs and malaria diagnostics, among anti-malarial-stocking outlets

	Private Sector Total N = 2596 (95% CI)	Eastern (N = 785) (95% CI)	Central (N = 350) (95% CI)	Western (N = 823) (95% CI)	Coastal N = (638) (95% CI)
Availability of anti-malarials^a
Any ACT^b	41.7 (36.9, 46.6)	65.6 (59.5, 71.2)	36.7 (27.6, 46.8)	14.1 (11.2, 17.5)	19.0 (14.2, 25.0)
Chloroquine	41.8 (38.4, 45.3)	24 (20.1, 28.3)	43.5 (37.0, 50.2)	47.7 (41.6, 53.8)	68.6 (62.4, 74.2)
Primaquine	7.7 (4.9, 10.4)	7.5 (5.4, 10.4)	11.1 (6.4, 18.4)	2.9 (1.6, 5.2)	1.0 (0.5, 1.9)
Oral AMT	27.7 (23.8, 31.7)	25.0 (18.9, 32.4)	31.4 (24.8, 38.9)	54.1 (49.4, 58.7)	15.4 (11.7, 20.2)
Non-oral AMT	11 (8.6, 13.4)	11.7 (7.7, 17.3)	11.8 (8.6, 16.2)	18.3 (15.0, 22.2)	5.5 (3.3, 9.0)

	N = 2890	N = 904	N = 398	N = 877	N = 711
Availability of blood testing^c
Any malaria blood testing	15.4 (12.6, 18.1)	21.0 (17.2, 25.4)	14.8 (10.4, 20.5)	8.4 (6.0, 11.7)	8.7 (5.7, 13.0)
Malaria microscopy	0.6 (0.2, 0.9)	0.6 (0.3, 1.2)	0.7 (0.2, 2.0)	0.7 (0.3, 1.5)	0.2 (0.0, 0.8)
RDTs	14.9 (12.3, 17.6)	20.5 (16.7, 24.8)	14.2 (9.9, 19.8)	8.2 (5.8, 11.4)	8.7 (5.7, 13.0)

AMT artemisinin monotherapy
^aAnti-malarial-stocking outlets have at least one anti-malarial in stock on the day of the survey, verified by presence of at least one anti-malarial recorded in the anti-malarial audit sheet
^bAt the time of the 2015/2016 Myanmar ACTwatch outlet survey, AL, DHA-PP, and ASMQ were the first-line treatments for uncomplicated falciparum malaria. There was no ASMQ audited during the 2015/2016 survey
^cBlood testing availability is reported among outlets that either had anti-malarials in stock on the day of the survey or reportedly stocked anti-malarials in the previous 3 months

ISSN: 1475-2875